CureVac NV (CVAC) Stock Analysis

CureVac NV (CVAC) is a publicly traded company in the HEALTHCARE sector. It trades at $4.66, carries a market capitalization of $1.05B, a price-to-earnings ratio of 6.96. This page summarizes the public market data, fundamentals, and frequently asked questions for CVAC, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $4.66
• Market Cap: $1.05B
• P/E Ratio: 6.96
• EPS: $0.67
• 52-Week High: $5.72
• 52-Week Low: $4.00

Market Sentiment

CureVac NV currently has a Bullish sentiment score of 0.22.

About CureVac NV

CureVac NV (CVAC) is a leading clinical-stage biopharmaceutical company headquartered in Tübingen, Germany, focused on developing innovative therapies based on messenger ribonucleic acid (mRNA) technology. The company is committed to addressing significant unmet medical needs by advancing a diverse pipeline of mRNA-based vaccines and therapeutics across various indications, including infectious diseases and oncology. With its robust scientific platform and strategic partnerships, CureVac is w...

GNG Research Analysis

GNG Research scores CureVac NV (CVAC) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CVAC.

Frequently Asked Questions

Does CVAC pay dividends?

CureVac NV (CVAC) does not currently pay a regular dividend.

What is CVAC's P/E ratio?

CureVac NV has a price-to-earnings (P/E) ratio of 6.96.

What is CVAC's market cap?

CureVac NV (CVAC) has a market capitalization of $1.05B with a current stock price of $4.66.